Skip to main content
OpenTrials
Completed

NCT Number: NCT03018808

Prevalence of Chronic Obstructive Pulmonary Disease (COPD) and Eosinophilia Among Primary Care Patients

Early diagnosis and appropriate treatment for COPD subjects are both critical to minimize the progression of COPD and improve outcomes. Also, evidence suggests that high eosinophil (specific type of white blood cell that protects body against certain kinds of germs) level is associated with increased risk of both moderate and severe exacerbations in COPD subjects. To date, there is insufficient amount of data that describes the prevalence of COPD in Brazilian primary care units. Thus, this multicenter, cross-sectional study conducted in five centers located in five different Brazilian cities will provide estimation about the prevalence of COPD in primary care and will also determine the levels of eosinophils in subjects with confirmed COPD diagnosis. Approximately 2,500 eligible subjects are expected to be enrolled in the study.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Pulmonary Disease, Chronic Obstructive Chronic Disease Disease Attributes Eosinophilia Hematologic Diseases Hemic and Lymphatic Diseases Leukocyte Disorders Lung Diseases Lung Diseases, Obstructive Pathologic Processes Pathological Conditions, Signs and Symptoms Respiratory Tract Diseases

Age range

35 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

GSK Investigational Site, Londrina, Paraná, Brazil

Loading trial locations.

About this study

The study is a cross sectional (prevalence study).

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adult >= 35 years old
  • At least one of the following risk factors for COPD:
  • being a current smoker (who has smoked 100 cigarettes in his or her lifetime and who currently smokes cigarettes) or past smoker (who has smoked at least 100 cigarettes in his or her lifetime but who had quit smoking at the time of interview); Current or past exposure to biomass smoke, such as wood or coal, for cooking or heating (exposure >=100 hours/year
  • Capable of giving signed informed consent

Exclusion criteria

  • Physical or mental disability to complete the study procedures
  • Heart above 120 beats per minute
  • Participants under treatment for tuberculosis
  • Participant in current clinical trial
  • Pregnancy
  • Patients with one of the following contraindications to spirometry: chest surgery in the last month; abdominal surgery within the past three months; neuromuscular disease, acute coronary syndrome; retinal detachment; hospitalization for any cardiac problem in the prior 3 months.

Treatment and study plan

Minimal questionnaire

Other

The minimal questionnaire is a reduced version of the medical interview and it will include questions about sociodemographic information, previous diagnosis of COPD, co-morbidities and smoking habits.

Medical interview

Other

Medical interview includes medical history, sociodemographic and clinical information, including disease history, treatment history, smoking habits and use of biomass.

CAT

Other

The CAT is a questionnaire for COPD patients and is designed to measure the impact of COPD on a person's life over time.

Blood test

Procedure

Blood samples will be collected at indicated time points

Anthropometric measures

Other

Anthropologic measures will be performed.

Oximetry

Other

Digital pulse oximeter on the index finger after five minutes rest and before receiving bronchodilator for spirometry will be used to measure the pulse arterial oximetry. The average of three measurements at 10 second intervals will be recorded. The heart rate will be provided by the pulse oximeter.

Primary outcomes

  1. Number of subjects with spirometry confirmed COPD diagnosis according to Fixed Ratio Criteria

    Time frame: Day 1

    Spirometry confirmed COPD diagnosis according to fixed ratio criteria will be defined as those with post-Bronchodilatador (BD) Forced Expiratory Volume in 1 second (FEV1)/ Forced Vital Capacity (FVC) < 0.7 among the total of patients with valid spirometry. Spirometry tests will be performed at Baseline and 15 minutes after the administration of 400 microgram (mcg) Salbutamol.

  2. Number of subjects with spirometry confirmed COPD diagnosis according to Lower Limit of Normal (LLN) Criteria

    Time frame: Day 1

    Spirometry confirmed COPD diagnosis according to Lower limit of normal (LNN) criteria will be defined as those with lower 5th percentile for predicted post-BD FEV1/FVC Spirometry tests will be performed at Baseline and 15 minutes after the administration of 400 mcg Salbutamol.

  3. Number of subjects who self-reported physician diagnosis of COPD

    Time frame: Day 1

    Number of subjects that self-report physician diagnosis of emphysema, chronic bronchitis, or COPD.

  4. Number of subjects with under diagnosed COPD

    Time frame: Day 1

    Number of subjects who meet the spirometry confirmed criteria of COPD (post-BD FEV1/FVC<0.7) but do not self-report medical diagnosis of emphysema, chronic bronchitis, or COPD.

  5. Number of subjects with physician COPD diagnosis

    Time frame: Day 1

    Number of subjects who meet the spirometry confirmed criteria of COPD(post-BD FEV1/FVC<0.7) and self-report medical diagnosis of emphysema, chronic bronchitis, or COPD.

  6. Number of subjects with misdiagnosed COPD

    Time frame: Day 1

    Number of subjects who do not meet the spirometry confirmed criteria of COPD but self-report diagnosis of emphysema, chronic bronchitis, or COPD.

Secondary outcomes

  1. Number OF COPD subjects classified by Global Initiative for Chronic Obstructive Lung Disease (GOLD) Severity Groups

    Time frame: Day 1

    COPD subjects will be classified using the following severity classification: GOLD 2007 (GOLD, 2007); GOLD 2013 (GOLD, 2013); GOLD 2017 (GOLD, 2017).

  2. Mean Charlson Comorbidity Index (CCI) score

    Time frame: Day 1

    All comorbidities included in the CCI will be investigated. The CCI contains 19 categories of comorbidity and predicts the ten-year mortality for a subject who may have a range of co-morbid conditions.

  3. Descriptive statistics for COPD Assessment Test (CAT) score

    Time frame: Day 1

    Mean, Median, Max-Min, Q1-Q3 for CAT score will be described.

  4. Number of subjects with mild exacerbation

    Time frame: Day 1

    Mild exacerbation will be defined as the deterioration of breathing symptoms that affected usual daily activities self-reported by the subject.

  5. Number of subjects moderate exacerbation

    Time frame: Day 1

    Moderate exacerbation will be defined as the one for which subjects need to take antibiotic and/or systemic corticosteroid due to increase of cough, phlegm or breathlessness.

  6. Number of subjects with severe exacerbation

    Time frame: Day 1

    Proportion of patients that needed to be hospitalized due to increase of cough, phlegm or breathlessness

  7. Assessment of treatment used in the last 14 days and an last year

    Time frame: Day 1

    Subjects will report the COPD medication used in the last 14 days and in the last year.

  8. Type of access to treatment

    Time frame: Day 1

    Subject will report where the medication (s) were obtained from (Public Health System, commercial pharmacy, charity institution/church, Brazilian Popular Pharmacy Program, free sample, friends/family/neighbor or other) at the last time they need such medication.

  9. Number of subjects with Asthma-COPD Overlap (ACO)

    Time frame: Day 1

    It will be considered two definitions for considering a patient with ACO: 1) Subjects with Spirometry confirmed COPD post- BD increase in FEV1 or FVC of 200 milliliter (mL) and 12 percent plus self-reported wheezing in the last 12 months reported on the medical interview among all subjects with spirometry confirmed COPD. 2) subjects having a spirometry confirmed COPD and self-reported asthma physician diagnosis among all subjects with spirometry confirmed COPD.

  10. Descriptive statistics for blood eosinophil's concentration

    Time frame: Day 1

    Geometric mean accompanied with 95% confidence intervals

  11. Number of subjects with blood eosinophil's < 150, >= 150; <300 and >= 300 Cells/Microliter

    Time frame: Day 1

    A 5 mL sample of venous blood will be collected from each subject in order to have the complete blood count with differential count.

  12. Number of subjects classified by Brazilian Society of Pulmonology and Physiology (SBPT) severity groups

    Time frame: Day 1

    COPD subjects will be classified using the SBPT 2017 classification system.

  13. Descriptive statistics for FEV1

    Time frame: Day 1

    Descriptive statistics for FEV1 will be summarized.

  14. Mean CCI score as a measure of clinical characteristics by ACO definitions

    Time frame: Day 1

    All comorbidities included in the CCI will be investigated. The CCI contains 19 categories of comorbidity and predicts the ten-year mortality for a subject who may have a range of co-morbid conditions. Each condition is assigned a score of 1, 2, 3, or 6, depending on the risk of dying associated with each one.

  15. Descriptive statistics for CAT score as a measure of clinical characteristics by ACO definitions

    Time frame: Day 1

    Mean, Median, Max-Min, Q1-Q3 for CAT score will be described.

  16. Descriptive statistics for FEV1 as a measure of clinical characteristics by ACO definitions

    Time frame: Day 1

    Descriptive statistics for FEV1 will be summarized.

  17. Number of subjects with mild exacerbation by ACO definition

    Time frame: Day 1

    Mild Exacerbation will be defined as the deterioration of breathing symptoms that affected usual daily activities self-reported by the subject.

  18. Number of subjects with moderate exacerbation by ACO definition

    Time frame: Day 1

    Moderate exacerbation will be defined as the one for which subjects need to take antibiotic and/or systemic corticosteroid due to increase of cough, phlegm or breathlessness.

  19. Number of subjects with severe exacerbation by ACO definition

    Time frame: Day 1

    Proportion of patients that needed to be hospitalized due to increase of cough, phlegm or breathlessness.

  20. Mean CCI score as a measure of clinical characteristics of eosinophil groups

    Time frame: Day 1

    All comorbidities included in the CCI will be investigated. The CCI contains 19 categories of comorbidity and predicts the ten-year mortality for a subject who may have a range of co-morbid conditions.

  21. Descriptive statistics for CAT score as a measure of clinical characteristics of eosinophil groups

    Time frame: Day 1

    Mean, Median, Max-Min, Q1-Q3 for CAT score will be described. Subjects identified with COPD will complete the CAT to measure the impact of COPD on a person's life.

  22. Descriptive statistics for FEV1 as a measure of clinical characteristics of eosinophil groups

    Time frame: Day 1

    Descriptive statistics for FEV1 will be summarized.

  23. Number of subjects with mild exacerbation of eosinophil groups

    Time frame: Day 1

    Mild Exacerbation will be defined as the deterioration of breathing symptoms that affected usual daily activities self-reported by the subject.

  24. Number of subjects with moderate exacerbation of eosinophil groups

    Time frame: Day 1

    Moderate exacerbation will be defined as the one for which subjects need to take antibiotic and/or systemic corticosteroid due to increase of cough, phlegm or breathlessness.

  25. Number of subjects with severe exacerbation of eosinophil groups

    Time frame: Day 1

    Proportion of patients that needed to be hospitalized due to increase of cough, phlegm or breathlessness.

Sponsors and collaborators

Lead sponsor

GlaxoSmithKline

Industry

Registry information

Official study title

A Cross-sectional Study to Characterize the Prevalence of COPD and Eosinophilia Among Primary Care Patients in Brazil

Important dates

Study start
2019
Primary completion
2021
Study completion
2021
First posted
Jan 12, 2017
Registry last updated
Apr 12, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.